首页> 外国专利> monomeric and dimeric forms of adiponectin receptor fragments and methods of use

monomeric and dimeric forms of adiponectin receptor fragments and methods of use

机译:脂联素受体片段的单体和二聚体形式及其使用方法

摘要

A method of determining the progression, initiation, or efficacy of diabetes treatment characterized by an adipocyte imbalance in a patient, comprising: determining a level of a peptide in a sample of biological fluid obtained from said patient; wherein said peptide is selected from the group consisting of: a first heterodimer comprising a first grouper unit and a second grouper unit, wherein said first grouper unit has at least approximately 90% identity with SEQ ID NO: 5 and wherein said second mer unit has at least about 90% identity with SEQ ID NO: 6, and wherein said first mer unit and said second mer unit are joined via a disulfide bond; a first homodimer comprising a first grouper unit and a second grouper unit, wherein said first grouper unit has at least approximately 90% identity with SEQ ID NO: 6 and wherein said second grouper unit is at least approximately 90% identity with SEQ ID NO: 6, and wherein said first mer unit and said second mer unit are joined via a disulfide bond; a second heterodimer comprising a first grouper unit and a second grouper unit, wherein said first grouper unit has at least approximately 90% identity with SEQ ID NO: 1 and wherein said second grouper unit is at least approximately 90% identity with SEQ ID NO: 6, and wherein said first mer unit and said second mer unit are linked through a disulfide bond; a third heterodimer comprising a first grouper unit and a second grouper unit, wherein said first grouper unit has at least approximately 90% identity with SEQ ID NO: 2 and wherein said second grouper unit is at least approximately 90% identity with SEQ ID NO: 6, and wherein said first mer unit and said second mer unit are linked through a disulfide bond; a dimer of said first heterodimer; a dimer of said first homodimer; a dimer of said second heterodimer; a dimer of said third heterodimer; and correlating the level of said selected peptide with said progression of onset of or efficacy of diabetes treatment.
机译:一种确定以患者中的脂肪细胞失衡为特征的糖尿病治疗的进展,开始或功效的方法,包括:确定从所述患者获得的生物液样品中的肽水平;其中所述肽选自由以下组成的组:包含第一石斑鱼单元和第二石斑鱼单元的第一异二聚体,其中所述第一石斑鱼单元与SEQ ID NO:5具有至少约90%的同一性,并且其中所述第二mer单元具有与SEQ ID NO:6具有至少约90%的同一性,并且其中所述第一mer单元和所述第二mer单元通过二硫键连接;第一同源二聚体,其包括第一石斑鱼单元和第二石斑鱼单元,其中所述第一石斑鱼单元与SEQ ID NO:6具有至少约90%的同一性,并且其中所述第二石斑鱼单元与SEQ ID NO:6具有至少约90%的同一性: 6,其中所述第一单体单元和所述第二单体单元通过二硫键连接;第二异二聚体,其包括第一石斑鱼单元和第二石斑鱼单元,其中所述第一石斑鱼单元与SEQ ID NO:1具有至少约90%的同一性,并且其中所述第二石斑鱼单元与SEQ ID NO:1具有至少约90%的同一性: 6,其中所述第一单体单元和所述第二单体单元通过二硫键连接;第三异二聚体,其包含第一石斑鱼单元和第二石斑鱼单元,其中所述第一石斑鱼单元与SEQ ID NO:2具有至少约90%的同一性,并且其中所述第二石斑鱼单元与SEQ ID NO:2具有至少约90%的同一性: 6,其中所述第一单体单元和所述第二单体单元通过二硫键连接;所述第一异二聚体的二聚体;所述第一同源二聚体的二聚体;所述第二异二聚体的二聚体;所述第三异二聚体的二聚体;使所述选择的肽的水平与所述糖尿病治疗的发作或疗效相关。

著录项

  • 公开/公告号ES2693165T3

    专利类型

  • 公开/公告日2018-12-07

    原文格式PDF

  • 申请/专利权人 SIEMENS HEALTHCARE DIAGNOSTICS INC.;

    申请/专利号ES20100767527T

  • 发明设计人 PUGIA MICHAEL;MA RUI;

    申请日2010-04-13

  • 分类号G01N33/53;

  • 国家 ES

  • 入库时间 2022-08-21 11:59:32

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号